Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 7/20 | 0.57 |
| ▸ | NMUR1 | Q9HB89 | 7/20 | 0.57 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | RAMP3 | O60896 | 3/20 | 0.52 |
| ▸ | CALCR | P30988 | 3/20 | 0.52 |
| ▸ | TFPI | P10646 | 1/20 | 0.52 |
| ▸ | NPY1R | P25929 | 1/20 | 0.52 |
| ▸ | NPY2R | P49146 | 1/20 | 0.52 |
| ▸ | NPY4R | P50391 | 1/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13807693 | 0.87 | NTSR2 (0.56) | NTSR1KDM1ANPY1RNPY2RNPY4R | |
| SCHEMBL14524262 | 0.84 | EPHA2 (0.59) | NTSR1KDM1ANPY1RNPY2RNPY4R | |
| SCHEMBL30953200 | 0.83 | NMUR2 (0.55) | NMUR2NMUR1C5AR1NTSR1RAMP3 | |
| SCHEMBL14546576 | 0.83 | NMUR2 (0.59) | NMUR2NMUR1NTSR1OPRD1NPY1R | |
| SCHEMBL13807691 | 0.83 | EPHA2 (0.57) | NTSR1NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL13807701 | 0.82 | EPHA2 (0.57) | NTSR1KDM1ANPY1RNPY2RNPY4R | |
| SCHEMBL13402655 | 0.81 | NMUR2 (0.61) | NMUR2NMUR1NTSR1NPY1RNPY2R | |
| SCHEMBL13402688 | 0.81 | NMUR2 (0.61) | NMUR2NMUR1NTSR1NPY1RNPY2R | |
| SCHEMBL9807268 | 0.81 | KDM1A (0.57) | KDM1ATFPIEPHA2 | |
| SCHEMBL31519869 | 0.80 | OPRD1 (0.64) | NTSR1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156507-A1 | Cell permeable conjugates of peptides for inhibition of protein kinases | CUREGENICS LTD. | 2009-06-18 | — | — | US | disclosed |
| US-20070078092-A1 | Cell permeable conjugates of peptides for inhibition of protein kinases | CUREGENICS LTD. (IL) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078092-A1 | Cell permeable conjugates of peptides for inhibition of protein kinases | MAP3K20, MAP3K19, MAP4K2 | NMUR2 3650/4885NMUR1 3400/4885C5AR1 2480/4885 |
| US-20090156507-A1 | Cell permeable conjugates of peptides for inhibition of protein kinases | MAP3K20, MAP3K19, MAP4K2 | NMUR2 3650/4885NMUR1 3400/4885C5AR1 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.